- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00125788
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary purpose of this study is to evaluate the effectiveness of oral L-glutamine in the therapy of sickle cell anemia and sickle ß0-thalassemia.
The secondary purpose is to assess the effect of L-glutamine frequency of hospitalizations for sickle cell pain, frequency of emergency room visits for sickle cell pain; energy and appetite levels; narcotics usage.
Methodology:
By site, patients will be randomized to L-glutamine or placebo in a 1:1 ratio after a 4-week screening period. Patients will undergo 48 weeks of treatment with dosing BID orally, with dose calculated according to patient weight. Patient visits will occur every 4 weeks. After 48 weeks of treatment, dose will be tapered to zero within 3 weeks. A final evaluation visit will occur 2 weeks after last dose.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Bellflower, California, United States, 90706
- Kaiser Permanente
-
Torrance, California, United States, 90502
- Harbor-UCLA Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- University of Medicine and Dentistry, New Jersey
-
-
New York
-
Bronx, New York, United States, 10461
- Jacobi Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible to participate in the study, a patient must meet all of the following inclusion criteria:
- Patient is at least five years of age.
- Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis).
- Patient has had at least two episodes of painful crises within 12 months of the screening visit.
- If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months.
- Patient or the patient's legally authorized representative has given written informed consent.
- If the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study.
Exclusion Criteria:
If the patient meets any of the following criteria, the patient must not be enrolled:
- Patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit.
- Patient has diabetes mellitus with untreated fasting blood sugar >115 mg/dL.
- Patient has prothrombin time International Normalized Ratio (INR) > 2.0.
- Patient has serum albumin < 3.0 g/dl.
- Patient has received any blood products within three weeks of the screening visit.
- Patient has a history of uncontrolled liver disease or renal insufficiency.
- Patient is pregnant or lactating.
- Patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit.
- Patient has been treated with an experimental drug within 30 days of the screening visit.
- There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: investigational product
L-glutamine
|
Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Other Names:
|
Placebo Comparator: placebo
maltodextrin
|
Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Occurrences of Painful Sickle Cell Crises
Time Frame: From Week 0 through Week 48 (cumulative)
|
The mean number of painful sickle crisis through week 48
|
From Week 0 through Week 48 (cumulative)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Hospitalizations for Sickle Cell Pain
Time Frame: From Week 0 through Week 48 (cumulative)
|
The mean number of hospitalizations through week 48
|
From Week 0 through Week 48 (cumulative)
|
Frequency of Emergency Room Visits for Sickle Cell Pain
Time Frame: From Week 0 through Week 48 (cumulative)
|
The mean number of emergency room visits through week 48
|
From Week 0 through Week 48 (cumulative)
|
The Effect of Oral L-glutamine on Hematological Parameters - Hemoglobin
Time Frame: Baseline, Weeks 4, 24 and 40
|
Patient's hemoglobin will be collected at each visit.Change from Baseline will be reported at Weeks 4, 24 and 40.
|
Baseline, Weeks 4, 24 and 40
|
The Effect of Oral L-glutamine on Hematological Parameters - Hematocrit
Time Frame: Baseline, Weeks 4, 24, and 40
|
Patient's hematocrit will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24 and 40
|
Baseline, Weeks 4, 24, and 40
|
The Effect of Oral L-glutamine on Hematological Parameters - Reticulocyte Count
Time Frame: Baseline, Weeks 0, 4, 24, 40
|
Patient's reticulocyte count will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24 and 40
|
Baseline, Weeks 0, 4, 24, 40
|
Number of Participants With Narcotic Usage
Time Frame: Week 24, Week 48
|
Analysis of narcotic usage was performed for the subset of patients with any narcotic use who completed the study.
Changes in narcotic usage were determined by an independent consultant prior to database lock using morphine equivalents to determine relative use.
|
Week 24, Week 48
|
Energy Level (11-point Scale)
Time Frame: Collected at Week 0, 8, 16, 24, 32, 40, 48
|
The patient's energy level was evaluated at each visit using an 11 point scale from 0=extremely tired to 10=extremely energetic
|
Collected at Week 0, 8, 16, 24, 32, 40, 48
|
Patient Appetite (3-point Scale)
Time Frame: Collected at Week 0, 8, 16, 24, 32, 40, 48
|
Patient's appetite level was evaluated at each visit using a 3 point scale: above average, average and below average.
The parentages of patient at each visit whose appetite level was below, normal or above average were compared using CMH test (row mean scores) controlling for study center.
|
Collected at Week 0, 8, 16, 24, 32, 40, 48
|
The Effect of Oral L-glutamine on Vital Signs - Blood Pressure
Time Frame: Baseline, Weeks 4, 24, and 48
|
Patient's blood pressure will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24, and 48
|
The Effect of Oral L-glutamine on Vital Signs - Temperature
Time Frame: Baseline, Weeks 4, 24, and 48
|
Patient's temperature will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24, and 48
|
The Effect of Oral L-glutamine on Vital Signs - Respiration
Time Frame: Baseline, Weeks 4, 24, and 48
|
Respiration will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24, and 48
|
The Effect of Oral L-glutamine on Vital Signs - Pulse Rate
Time Frame: Baseline, Weeks 4, 24, and 48
|
Patient's pulse rate will be collected at each visit, Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24, and 48
|
Effect of L-glutamine on Alcohol Use
Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48
|
The patient's alcohol usage will be assessed at each visit.
Alcohol usage will be reported at Weeks 0, 8,16, 24, 32, 40 and 48
|
Weeks 0, 8,16, 24, 32, 40 and 48
|
Effect of L-glutamine on Tobacco Use
Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48
|
Patient's alcohol usage will be assessed at each visit.
Alcohol usage will be reported at Weeks 0, 8,16, 24, 32, 40 and 48
|
Weeks 0, 8,16, 24, 32, 40 and 48
|
The Effect of Oral L-glutamine on the Number of Days Patient's Daily Activities Are Interrupted Due to Sickle Cell Pain
Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48
|
Percentage of days a patient's daily activities were interrupted due to sickle pain calculated at each visit.
Day's interrupted will be reported at Weeks 0, 8,16, 24, 32, 40 and 48
|
Weeks 0, 8,16, 24, 32, 40 and 48
|
The Effect of Oral L-glutamine on Subjective Quality of Life
Time Frame: Baseline and Week 24 (or at time of discontinuation)
|
The subjective quality of life was evaluated using the scoring of the RAND 36-Item Health Survey Questionnaire.
The subjective quality of life (Physical functioning, Physical health, Emotional problems, Energy/Fatigue, Emotional well being, Social functioning, Pain, General health) will be reported at Baseline and Week 24 (or at time of discontinuation).
The range for Physical functioning, Physical health, Emotional problems, Emotional well being and Social functioning is 0-100, with a high score denotes a better quality of life.
For Energy/Fatigue, Pain and General health the range is 0-100, with a lower score denotes better quality of life.
|
Baseline and Week 24 (or at time of discontinuation)
|
Effect of Oral L--glutamine on Height
Time Frame: Baseline, Weeks 4, 24, and 48
|
Height will be measured at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24, and 48
|
Effect of Oral L--glutamine on Weight
Time Frame: Baseline, Weeks 4, 24 and 48
|
Weight will be measured at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48
|
Baseline, Weeks 4, 24 and 48
|
Effect of L-glutamine on Subjective Exercise Tolerance - Minutes Patient Could Walk Without Rest
Time Frame: Baseline, Weeks 4, 24, and 48.
|
Minutes patient could walk without rest will be measured at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48.
|
Baseline, Weeks 4, 24, and 48.
|
Effect of L-glutamine on Subjective Exercise Tolerance - Minutes Patient Could Run Without Rest
Time Frame: Baseline, Weeks 4, 24, and 48.
|
Minutes patient could run without rest will be measured at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48.
|
Baseline, Weeks 4, 24, and 48.
|
Effect of L-glutamine on Subjective Exercise Tolerance - Distance Patient Could Walk Without Rest
Time Frame: Baseline, Weeks 4, 24, and 48.
|
Distance patient could walk without rest will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48.
|
Baseline, Weeks 4, 24, and 48.
|
Effect of L-glutamine on Subjective Exercise Tolerance - Distance Patient Could Run Without Rest
Time Frame: Baseline, Weeks 4, 24, and 48.
|
Distance patient could run without rest will be collected at each visit.
Change from Baseline will be reported at Weeks 4, 24, and 48.
|
Baseline, Weeks 4, 24, and 48.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yutaka Niihara, MD, CEO, Emmaus Medical, Inc
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10478
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Anemia
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
National Institute of Diabetes and Digestive and...RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell TraitUnited States
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSickle Cell Anemia in ChildrenUganda
Clinical Trials on L-glutamine
-
Emmaus Medical, Inc.Completed
-
Hawaii Pacific HealthUnknown
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedPain | Head and Neck Cancer | Cancer-related Problem/ConditionCanada, United States
-
University of AlbertaCompleted
-
Scandinavian Critical Care Trials GroupTerminated
-
Instituto Mexicano del Seguro SocialCompletedInsufficiency;CardiacMexico
-
Eastern Regional Medical CenterTSPC America, Inc.WithdrawnPeripheral NeuropathyUnited States
-
Meshalkin Research Institute of Pathology of CirculationCompletedCoronary Artery DiseaseRussian Federation
-
Tulane UniversityCompletedDiarrhea-Predominant Irritable Bowel SyndromeUnited States
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnColorectal Cancer | Metastasis | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal